Lexaria Bioscience Corp. (LEXX)
NASDAQ: LEXX · Real-Time Price · USD
0.7025
-0.0095 (-1.33%)
Mar 12, 2026, 1:45 PM EDT - Market open
Lexaria Bioscience Employees
Lexaria Bioscience had 7 employees as of August 31, 2025. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$74,571
Profits / Employee
-$1,541,878
Market Cap
17.48M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Aug 31, 2025 | 7 | 0 | - |
| Aug 31, 2024 | 7 | 2 | 40.00% |
| Aug 31, 2023 | 5 | -2 | -28.57% |
| Aug 31, 2022 | 7 | 1 | 16.67% |
| Aug 31, 2021 | 6 | 2 | 50.00% |
| Aug 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| IO Biotech | 78 |
| Citius Pharmaceuticals | 23 |
| IN8bio | 17 |
| Reviva Pharmaceuticals Holdings | 14 |
| Serina Therapeutics | 13 |
| VYNE Therapeutics | 13 |
| Genenta Science | 13 |
| Intensity Therapeutics | 7 |
LEXX News
- 8 days ago - Lexaria Announces New R&D Plans for 2026 - Accesswire
- 5 weeks ago - Lexaria Announces Positive Final Results From Human Pilot Study #5 - Accesswire
- 7 weeks ago - Lexaria Awarded Six Additional Patents - Accesswire
- 2 months ago - Lexaria Releases Annual Letter from the CEO - Accesswire
- 2 months ago - Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4 - Accesswire
- 2 months ago - Lexaria Says Oral GLP-1 Cuts Side Effects Nearly 50% Versus Novo Nordisk's Rybelsus - Benzinga
- 2 months ago - Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4 - Accesswire
- 3 months ago - Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Accesswire